

REMARKS

This communication is made in response to the restriction requirement dated May 7, 2010 (the Restriction Requirement). Currently, claims 1-19, 21, 25, 26 and 29 are pending.

The Restriction Requirement separated the claims into Group I (claims 1-15, 21, 25-26) drawn to a fusion protein complex and Group II (claims 16-19) drawn to an isolated nucleic acid encoding a fusion protein complex.

In response, Applicants elect Group I, consisting of claims 1-15, 21, 25 and 26 without traverse.

The Restriction Requirement further set forth a species election requiring selection of a species of A from claim 2 and B from claim 7. This election is understood to be for purposes of a first search of the prior art, with further species being examined if the elected species are deemed allowable.

In response, Applicants elect A as "scFv" from claim 2 (single chain antibody fragment, please note definition at ¶46 of published Application). And B is elected as "DAP kinase-related protein kinase 1 (DRP-1), also named DAP-kinase 2 (DAPk2)" from claim 7.

The Examiner is invited to telephone the undersigned if the Examiner believes it would be useful to advance prosecution.

Respectfully submitted,

/Curtis B. Herbert/
Curtis B. Herbert, Ph.D., Reg. #45,443

Customer No. 62274
Dardi & Herbert, PLLC
Moore Lake Plaza, Suite 205
1250 East Moore Lake Drive
Fridley, MN 55432
Telephone: (763) 412-3820